

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Rasheduzzaman, M;Murugan, AVM;Zhang, X;Oliveira, T;Dolcetti, R;Kenny, L;Johnson, NW;Kolarich, D;Punyadeera, C

Title:

Head and neck cancer N-glycome traits are cell line and HPV status-dependent

Date:

2022-12-01

Citation:

Rasheduzzaman, M., Murugan, A. V. M., Zhang, X., Oliveira, T., Dolcetti, R., Kenny, L., Johnson, N. W., Kolarich, D. & Punyadeera, C. (2022). Head and neck cancer N-glycome traits are cell line and HPV status-dependent. *Analytical and Bioanalytical Chemistry*, 414 (29-30), pp.8401-8411. <https://doi.org/10.1007/s00216-022-04376-x>.

Persistent Link:

<https://hdl.handle.net/11343/335179>

License:

[CC BY](#)



# Head and neck cancer N-glycome traits are cell line and HPV status–dependent

Mohammad Rasheduzzaman<sup>1,2</sup> · Abarna V. M. Murugan<sup>3</sup> · Xi Zhang<sup>2</sup> · Tiago Oliveira<sup>3</sup> · Riccardo Dolcetti<sup>4,5,6,7</sup> · Liz Kenny<sup>8</sup> · Newell W. Johnson<sup>9</sup> · Daniel Kolarich<sup>3,10</sup> · Chamindie Punyadeera<sup>1,2,9</sup>

Received: 7 July 2022 / Revised: 5 October 2022 / Accepted: 10 October 2022 / Published online: 27 October 2022  
© The Author(s) 2022

## Abstract

Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC). In HNSCC, 5-year survival remains poor, averaging around 50% globally; this is partly related to late diagnosis. Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets. Nevertheless, HNSCC-specific glycome is to date largely unknown. Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry. Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5–70%). The levels of sialylated N-glycans showed considerable cell line-dependent differences ranging from 24 to 35%. Importantly,  $\alpha$ 2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of  $\alpha$ 2-6 and  $\alpha$ 2-3 sialylated N-glycans were observed. Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways. Almost all fucose-type N-glycans carried core-fucose residues with just minor levels (<4%) of Lewis-type fucosylation identified. We also observed paucimannose-type N-glycans (2–5.5%), though in low levels. Finally, we identified oligomannose N-glycans carrying core-fucose residues and confirmed their structure by tandem mass spectrometry. This first systematic mapping of the N-glycome revealed diverse and specific glycosylation features in HNSCC, paving the way for further studies aimed at assessing their possible diagnostic relevance.

**Keywords** Head and neck cancers · N-glycosylation · Glycomics · Sialic acid · Cell line · HPV

Tiago Oliveira is currently at Institute of Molecular Biotechnology Austrian Academy of Sciences (IMBA)Vienna, Austria.

✉ Daniel Kolarich  
d.kolarich@griffith.edu.au

✉ Chamindie Punyadeera  
c.punyadeera@griffith.edu.au

<sup>1</sup> Centre for Biomedical Technology, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, QLD, Australia

<sup>2</sup> Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD, Australia

<sup>3</sup> Institute for Glycomics, Griffith University, Gold Coast Campus, Southport 4222, QLD, Australia

<sup>4</sup> Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia

<sup>5</sup> Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia

<sup>6</sup> Department of Microbiology and Immunology, The University of Melbourne, Victoria 3010, Australia

<sup>7</sup> The University of Queensland Diamantina Institute, Brisbane, QLD, Australia

<sup>8</sup> Department of Radiation Oncology, Cancer Care Services, Royal Brisbane and Women's Hospital, Joyce Tweddell Building, Herston, QLD 4029, Australia

<sup>9</sup> Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia

<sup>10</sup> ARC Centre of Excellence for Nanoscale BioPhotonics, Griffith University, Gold Coast, QLD, Australia

## Introduction

Head and neck cancer (HNC) refers to a heterogeneous group of malignant neoplasms, with over half a million new cases diagnosed annually across the globe [1, 2]. Majority of them originate from lining mucosae and are collectively described as head and neck squamous cell carcinoma (HNSCC). These tumours can originate from the hypopharynx, oropharynx, lip, oral cavity, nasopharynx, or larynx with a range of well-established risk factors [3, 4]. Only about 50% of HNSCC patients live beyond 5 years [5].

Human papillomaviruses (HPV-16 and HPV-18; high-risk types) are small, double-stranded, circular DNA viruses that are responsible for a global epidemic of a subset of HNSCC, mainly originating in the lymphoid mucosa of the oropharynx (oropharyngeal cancers, OPC) [6, 7]. Current diagnostic practise requires an expert visual examination and imaging by X-radiography, CT scan and MRI in conjunction with tissue biopsy staging [8, 9]. Less invasive means to identify, stage and monitor treatment response in HNSCC are required to improve patient outcomes [10]. Glycosylation, a common post-translational modification (PTM) of proteins, has frequently been reported to undergo major changes that are associated with malignant transformation of epithelial cells [10]. Understanding the glycosylation features in most widely used HNSCC cell lines is an important prerequisite to investigate how protein glycosylation can provide novel diagnostic and therapeutic opportunities [2].

Though no comprehensive studies of the HNSCC N-glycome have been published to date, glycosylation changes have been reported in several studies. As an example, in saliva, the total sialic acid/total protein ratio as well as the activities of  $\alpha$ 2-3 and  $\alpha$ 2-6 sialyltransferases were reported to be significantly higher in patients with metastatic oral cancer [11]. Additionally, in patient sera, tri-antennary and tetra-antennary N-glycans with varying degrees of sialylation and fucosylation have been reported to be a potential diagnostic biomarker for oral squamous cell carcinoma (OSCC) [12]. Multiple fucosyltransferases such as FUT1, FUT2, FUT3 and FUT6 have also been associated with the high abundance of Lewis Y ( $Le^y$ ) and sialyl Lewis X ( $SLe^x$ ) epitopes, changes which are known to promote EGFR phosphorylation in OSCC cell lines [13, 14]. In OSCC tumour tissues, an overexpression of *MGAT5* (also known as GNT-V) enhanced CEACAM6 N-glycosylation, which in turn promoted EGFR signalling that correlated with poor prognosis [15]. Despite the above mentioned studies, a detailed map of the HNSCC cell N-glycome is still lacking. Furthermore, it is unknown if and how the expression of HPV infection impacts the HNSCC glycometabolism.

We employed a well-established porous graphitized carbon (PGC) glycomics platform [PGC liquid

chromatography (LC) electrospray ionisation tandem mass spectrometry (ESI-MS/MS)] to establish the first N-glycan map of the most widely used HNSCC cell lines (SCC-25, CAL-27, SCC-9, FaDu, 2A3 and VU-147 T), of which 2A3 and VU-147 T considered as HPV (+) cells. In addition, we have also investigated whether HPV infection affect the relative distribution of N-glycans. While the HNSCC cells analysed exhibited general similarities, distinct cell line-specific N-glycosylation traits were identified that make each cell line an individual research resource. Distinct differences were identified in sialic acid linkage distribution. Various levels of phosphorylated oligomannose, oligomannose and sialylated N-glycans were determined. We also confirmed that oligomannose N-glycans can act as a substrate for FUT8, as demonstrated by the presence of several core-fucosylated oligomannose-type N-glycan structures. This systematic N-glycome map of the most widely used HNSCC cell lines provides the first HNSCC-glycome reference dataset that builds the foundation for future glyco-biomarker research in HNSCC.

## Materials and methods

### Chemicals, reagent and equipment

Ethanol, methanol, glacial acetic acid and direct blue 71, polyvinylpyrrolidone (PVP40), ammonium hydroxide solution ( $\geq 25\%$  (vol/vol)  $NH_3$  in  $H_2O$ , sodium borohydride ( $NaBH_4$ ), potassium hydroxide (KOH), trifluoroacetic acid (TFA), LC-MS grade, water, fetuin from foetal calf serum, RPMI medium and foetal bovine serum (FBS) were obtained from Sigma-Aldrich. AG50W-X8 cation-exchange resin was purchased from BioRad. ZipTip with C18 resin and Immobilon-PSQ (0.45  $\mu$ m pore size) PVDF membranes were obtained from Millipore. RIPA buffer and Pierce<sup>TM</sup> BCA protein assay kit were purchased from Thermo Fisher Scientific. PNGase F was from New England Biolabs. Porous graphitized carbon columns were obtained from New Objectives (length 150 mm  $\times$  100  $\mu$ m I.D., 5  $\mu$ m particle size). The SpeedVac concentrator was from Thermo Fisher Scientific. Acetonitrile LC-MS grade was purchased from Merck.

### Origin of cell lines and cell culture

All the HNSCC cell lines were STR profiled and authenticated. This gave us the confidence that our cell lines are correctly identified, and not cross-contaminated with other cells. In addition, we have also performed mycoplasma testing using Lonza's MycoAlert<sup>®</sup> Mycoplasma Detection Assays and were confirmed to be of mycoplasma free. Six HNSCC cell lines, including two HPV positive, were

purchased from ATCC (American Type Culture Collection) or a generous gift (Supplementary Table 1). Cell culture was performed according to ATCC guidelines. Cells were cultured under standard conditions in humidified incubators at 37 °C, 20% O<sub>2</sub>, 5% CO<sub>2</sub>. Briefly, 0.6–0.7 million cells were seeded into T75 mL flasks and incubated with medium consisting of RPMI-1640, 10% foetal bovine serum and penicillin/streptomycin, of which 2A3 cells were incubated with media consisting of hGlucose DMEM-10%FBS + 2 nM glutamine + G418 200 µg/mL. Once cells density reached to 85–90% confluence, we washed the cells twice with ice cold PBS. Cells were lysed and harvested (by scraping) in cold RIPA buffer with freshly added protease inhibitor cocktails. The next step was to vigorously vortex the cells thrice for 30 s followed by ultrasonication (an ultrasonic bath for 10 min). Cell lysates were centrifuged at 14,000 × g for 15 min at 4 °C. Supernatant was collected, and protein concentrations were measured using the BCA protein assay kit as per the manufacturer's instruction. After protein quantitation, (glyco)proteins were precipitated using ice cold (–20 °C) acetone. The resultant protein pellet was allowed to air dry at room temperature. The sample was resuspended using 8 M urea by intensive vortexing.

### Sample preparation and data acquisition

50 µg of (glyco)proteins were immobilised onto a 0.45 µm pore size PVDF, washed and stained with direct blue 71. N-glycans were released from glycoproteins using PNGase F as described previously [16, 17, 18]. Released N-glycans were then further reduced and desalted before subjected to PGC-LC-ESI MS/MS glycomics [16, 17, 18, 19] [see Supplementary Material (Supplementary Fig. 1) for experimental details reported in a MIRAGE (Minimum Information Required for A Glycomics Experiment) compliant manner [20, 21, 22, 23]].

### Data analysis and availability

N-glycan structures were determined as previously described [16, 18, 19]. GlyConnect Compozitor (<https://glyconnect.expasy.org/compozitor/>) was used to visualise the glycan network [24]. The relative intensities and statistical analysis (supplementary materials, pages 7–14) were determined using GraphPad Prism (v8.4.3) and presented with mean + SD. Bar graphs were generated from six replicates (two biological replicates, of which each group had three technical replicates).

The data is made available via GlycoPOST, accession number GPST000279, URL, <https://glycopost.glycosmos.org/previous/7702599506310db315e4be> PIN CODE: 4365 [25].

## Results


### HNSCC N-glycome features are cell line dependent

We profiled the N-glycome from six different, widely used HNSCC cell lines using PGC-nanoLC ESI MS/MS. Overall, we identified 99 different N-glycan structures that were present in 49 compositions (Supplementary Table 2). The integrity of the dataset was first verified using *GlyConnect Compozitor* network analysis to understand the biosynthetic connections between the identified N-glycans and to uncover any potential gaps in the acquired dataset (Fig. 1A) [24]. These data confirmed the majority of virtual nodes (not present in our dataset, generated by the software) to be derived from compositions unlikely to occur due to currently understood biosynthetic constraints [e.g. Hex4-HexNAc2-dHex1-NeuAc1 (H4N2F1S1)] or from known intermediate structures that are usually quickly processed into other structures (e.g. H4N4, or H5N3, Fig. 1A). This led us to conclude that the acquired dataset was not missing any glycans and that identified N-glycans were in good agreement with our current understanding of the N-glycan biosynthesis.

While the overall compositional profile was similar between the analysed cell lines, we observed a considerable diversity with respect to the quantitative distribution of the individual N-glycan structures (Table 1, Fig. 1B, Supplementary Table 3 and Supplementary Table 9). Oligomannose-type N-glycan levels ranged between 57.5–70% across all analysed cell lines, while complex-type N-glycans made up between 24 and 36% (Fig. 1B, Supplementary Table 5 and Supplementary Table 7). Overall, these two glycan families constituted the major components of the HNSCC cell line N-glycome. The levels of pauci-mannose and hybrid-type N-glycans were low and did in average not exceed 6% of the total N-glycome (Fig. 1B, Table 1 and Supplementary Table 4 and Supplementary Table 6).

### The impact of HPV infection on HNSCC cell glycosylation

Infection with HPV has been associated with an increased risk of developing HNSCC. It is well known that the HPV-positive HNSCC and HPV-negative HNSCC are biologically and clinically different [26, 27]. We then next investigated whether the presence of HPV genome or fragments thereof could impact the overall HNSCC cell N-glycome. VU-147 T is an HPV + cell line, while 2A3 is originally derived from FaDu cells and transfected with HPV type 16 E6 and E7 genes under control of the Moloney murine



**Fig. 1** HNSCC N-glycome features are cell line dependent. Quantitative distribution of major glycosyl categories. **A** GlyConnect network in acquired glycans dataset. **B** Quantitative distribution of four major glycan classes in six different HNSCC cells

leukaemia virus (MoMuLV) promoter-enhancer sequence [28]. Interestingly, VU-147 T exhibited the highest level of complex-type N-glycans (35.6%), while the opposite was found for 2A3, which was the cell line with the lowest level of complex-type N-glycans (23.7%; Table 1). The high level of complex-type N-glycans found in VU-147 T is particularly due to the higher levels of tri antennary and larger, not further structurally defined N-glycans (Fig. 2).

While the overall level of complex-type N-glycans differed significantly between cell lines (Table 1), almost all these structures carried one or more sialic acid(s). Notably, a strong reduction in complex-type N-glycans was found in 2A3 cells, while their originator cell line (FaDu) showed essentially similar levels to, e.g. VU-147 T cells (33.9%; Table 1). It remains unclear if that is the consequence of insertion of HPV type 16 E6 and E7 genes or a secondary, off-target effect. Such off-target effects impacting cellular glycosylation as a consequence of gene-editing have been reported earlier in ovarian cancer cells [29]. CRISPR-Cas9-mediated disruption of *B3GNT5*, a key transferase in the (neo-) lacto series glycosphingolipid biosynthesis, led to the unexpected depletion of  $\alpha$ 2-6 sialylated N-glycans due to the lack of *ST6GAL1* expression in the  $\Delta$ B3GNT5 cells [29]. It is conceivable that insertion of the E6 and E7 genes in combination with the neomycin resistance, which is associated with the used vector, led to a modulation of the glycosylation

features now observed for the 2A3 cell line that differs significantly from the parental FaDu cells (Fig. 1B).

### Sialylation is a major feature of complex-type N-glycans in HNSCC cells

With exception of SCC-25, where slightly higher levels of neutral complex-type N-glycans were identified (3.7%), the levels of neutral, complex-type N-glycans were around 1% or lower in all other cell lines (Fig. 3A). Thus, sialylation can be considered to be a major feature of complex N-glycans in all analysed HNSCC cell lines (Table 1). To better understand the type of N-acetylneuraminic acid (NeuAc) linkages across the different cell lines, we used PGC-LC glycomics approach that allows for an easy differentiation of NeuAc linkages on N-glycans [30, 31]. While SCC-9 showed an almost balanced ratio between  $\alpha$ 2-6 and  $\alpha$ 2-3 linked N-glycans (Fig. 3B), the levels of  $\alpha$ 2-6 linked NeuAc was up to four times the one of  $\alpha$ 2-3 linked NeuAc in all other cell lines (Fig. 3B). These higher levels of  $\alpha$ 2-6 linked NeuAc was largely independent of core-fucosylation except in VU-147 T, where non-core fucosylated N-glycans were four times more likely to carry  $\alpha$ 2-6 linked NeuAc, while core-fucosylated ones exhibited almost equal levels of  $\alpha$ 2-3 and  $\alpha$ 2-6 NeuAc (Fig. 3B). Interestingly, a similar link between NeuAc linkage and core-fucosylation has been

**Table 1** Average relative abundances (derived  $n=6$ ) of different N-glycan classes for six different HNSCC cell lines. Cell lines labelled with an \* are considered HPV + cell lines. Fuc considered as fucose. Standard deviation of data is included

Traits	VU-147 T*	SCC-25	CAL-27	SCC-9	FaDu	2A3*
Paucimannose	5.57(0.43)	4.97(0.66)	4.52(1.53)	4.62(1.42)	1.96(0.20)	4.45(2.11)
Paucimannose Fuc	4.12(0.24)	3.76(0.38)	3.39(0.95)	3.96(1.28)	1.48(0.13)	3.54(1.71)
Oligomannose	57.53(2.19)	66.36(2.26)	60.89(2.38)	61.07(1.07)	62.73(3.06)	70.27(0.66)
Oligomannose Fuc	0.42(0.07)	0.07(0.04)	0.23(0.02)	0.63(0.34)	0.16(0.05)	0.31(0.20)
Oligomannose Pho	5.85(0.85)	1.33(0.51)	3.65(0.31)	5.68(2.10)	2.80(0.68)	4.59(1.10)
Hybrid	1.27(0.18)	1.06(0.04)	2.28(0.61)	3.85(1.17)	1.42(0.11)	1.56(0.38)
Hybrid Fuc	0.32(0.07)	0.27(0.02)	0.86(0.30)	2.21(0.94)	0.42(0.04)	0.67(0.16)
Hybrid Sialyl	0.53(0.10)	0.47(0.04)	1.46(0.37)	2.16(0.62)	1.00(0.09)	1.07(0.21)
Hybrid Neutral	0.74(0.14)	0.59(0.04)	0.82(0.25)	1.68(0.62)	0.41(0.02)	0.50(0.19)
Hybrid $\alpha$ 2-6	0.37(0.10)	0.36(0.03)	1.10(0.43)	0.92(0.20)	0.68(0.12)	0.57(0.14)
Hybrid $\alpha$ 2-3	0.16(0.02)	0.11(0.02)	0.33(0.08)	1.20(0.48)	0.30(0.05)	0.45(0.07)
Hybrid ND	0.00(0.00)	0.00(0.00)	0.03(0.01)	0.04(0.01)	0.02(0.00)	0.04(0.02)
Hybrid, $\alpha$ 2-6 NeuAc, Fuc	0.01(0.01)	0.07(0.01)	0.38(0.22)	0.57(0.28)	0.19(0.01)	0.22(0.04)
Hybrid $\alpha$ 2-3 NeuAc, Fuc	0.03(0.01)	0.02(0.01)	0.14(0.05)	0.89(0.42)	0.10(0.04)	0.21(0.03)
Complex	35.63(2.21)	27.61(1.94)	32.31(0.86)	30.46(3.14)	33.90(3.06)	23.71(1.47)
Complex Fucosylated	3.29(0.32)	8.52(1.04)	10.28(0.69)	10.03(2.45)	7.54(1.81)	6.43(1.03)
Complex Sialylated	34.52(2.24)	23.88(2.28)	31.24(0.93)	29.75(3.16)	33.12(3.18)	22.93(1.42)
Complex Neutral	1.11(0.10)	3.73(0.36)	1.07(0.08)	0.71(0.05)	0.77(0.17)	0.78(0.08)
Complex $\alpha$ 2-6 NeuAc	5.40(0.55)	8.30(0.33)	9.84(1.91)	6.19(1.71)	9.04(0.46)	5.58(0.74)
Complex $\alpha$ 2-3 NeuAc	1.49(0.20)	1.93(0.20)	4.11(1.48)	7.04(2.03)	3.69(1.01)	3.49(0.71)
Complex ND	20.93(1.32)	9.80(1.22)	11.96(0.72)	11.00(2.01)	13.83(2.15)	9.74(0.53)
Complex Mix	6.70(0.45)	3.86(1.20)	5.32(0.44)	5.52(1.43)	6.56(1.75)	4.13(0.29)
Complex, $\alpha$ 2-6 NeuAc, Fuc	0.31(0.04)	4.13(0.48)	4.97(1.21)	2.36(0.58)	3.65(0.75)	2.50(0.47)
Complex, $\alpha$ 2-3 NeuAc, Fuc	0.70(0.04)	1.08(0.19)	2.74(1.12)	5.76(2.12)	2.17(0.77)	2.51(0.45)
Sialylation total	35.05(2.22)	24.35(2.30)	32.70(1.09)	31.91(2.58)	34.13(3.22)	24.00(1.58)
$\alpha$ 2-6 NeuAc total	5.77(0.55)	8.66(0.29)	10.94(2.32)	7.12(1.64)	9.71(0.53)	6.15(0.93)
$\alpha$ 2-3 NeuAc total	1.65(0.22)	2.04(0.18)	4.43(1.54)	8.24(2.50)	3.99(1.05)	3.94(0.78)
$\alpha$ 2-6 NeuAc + Fuc total	0.33(0.01)	4.20(0.56)	5.35(1.81)	2.93(1.29)	3.84(0.92)	2.72(0.63)
$\alpha$ 2-3 NeuAc + Fuc total	0.73(0.01)	1.10(0.24)	2.88(1.37)	6.65(0.05)	2.27(0.98)	2.72(0.54)
Sialylation ND	20.93(1.41)	9.80(1.27)	12.00(0.54)	11.04(0.18)	13.86(2.46)	9.79(0.38)
Mix $\alpha$ 2-6, $\alpha$ 2-3	6.70(0.47)	3.86(1.54)	5.32(0.18)	5.52(0.42)	6.56(2.17)	4.13(0.25)
Neutral	1.85(0.03)	4.32(0.45)	1.89(0.29)	2.39(0.40)	1.18(0.17)	1.28(0.32)
Fucosylation	8.15(0.32)	12.62(1.15)	14.76(2.42)	16.83(2.02)	9.61(2.41)	10.95(0.96)


previously observed for glycoproteins obtained from non-melanoma skin cancer biopsies [32], hinting towards some form of higher-level connection between core-fucosylation and sialylation linkage.

### Core fucosylation is the major form of fucosylation in HNSCC N-glycans

Fucose plays a major role as a component of cancer-associated glyco-epitopes such as (but not limited to) Lewis X or Lewis Y [10, 33]. Core fucose was the major form of fucosylation found across all analysed HNSCC cell lines, ranging from 8 (VU-147 T) to 18% of all N-glycans (SCC-9). Less than 1% of N-glycans carried Lewis-type fucose

residues (Fig. 4A), making this just a very minor proportion of glyco-epitopes in HNSCC cells. The levels of core-fucosylation, however, were distinctly different between cell lines and glycan-types.

Almost all paucimannose-type N-glycans were core-fucosylated (Fig. 4B). In Cal-27, SCC-9 and SCC-25, about one-third of all complex N-glycans carried a core-fucose. These levels were slightly lower in FaDu and 2A3 cells (around a quarter of all complex ones), but significantly lower in VU-147 T cells, where in average just one tenth of all complex N-glycans was core fucosylated (Fig. 4C). This clearly indicates towards a reduced expression of FUT8 in VU-147 T. While it is impossible to speculate about the cause for the indicated lower transcript or protein expression




**Fig. 2** The impact of HPV infection on HNSCC cell glycosylation. Distribution of sialylated glycan types in FaDu and 2A3 cells. Antennary (Bi antennary, Tri antennary) type glycan distribution in different cell lines

(or fucosyltransferase activity) of FUT8 in VU-147 T, the different origins of these cells (floor of mouth) might be a possible explanation as essentially all other cells are derived from epithelial origins (Supplementary Table 1).


**Phosphorylated oligomannose N-glycan levels vary across cell lines**

Mannose 6-phosphate (Man6P) is a common modification important to guide glycoproteins towards the lysosome via the Man-6-P receptor (M6PR) [34]. Thus, the levels of Man6P containing N-glycans could indicate towards an increased activity of lysosome. SCC-9 cells as well as the HPV + cell lines VU-147 T and 2A3 contained significantly higher levels of Man6P oligomannose-type N-glycans (up to 6% of the total N-glycan pool) compared to the other three cell lines that were between 1.5 and 3% (Fig. 5A). Independent of the overall level, all cell lines shared the same pattern that Man7 was by far the most abundant phosphorylated oligomannose N-glycan modified with up to two phosphate


**Fig. 3** Sialylation is a major feature of complex-type N-glycans in HNSCC cells. Quantitative distribution of NeuAc-linked glycan in the complex-type glycans. **A** Quantitation of complex neutral glycans. **B** Ratio of  $\alpha$ 2-6 vs  $\alpha$ 2-3 sialylated glycans and sialylation with fucosylation



**Fig. 4** Core fucosylation is the major form of fucosylation in HNSCC N-glycan. Distribution of fucosylated-type glycans. **A** Proportion of different categories of fucosylated types of glycan. **B** Fucosylation in paucimannosidic glycans. **C** Core fucose in complex-type glycan category



**Fig. 5** Phosphorylated oligomannose N-glycan levels vary across cell lines. Dissecting oligomannose-type glycan. **A** Quantitation of phosphate attached oligomannose glycans. **B** Quantitative distribution of different categories of oligomannose types across the cell lines. Man6p = Mannose 6 phosphate



residues, while phosphate attached to Man8 and Man6 was detected in far lower amounts (Fig. 5B). Given that Man8 was clearly the most abundant oligomannose structure across all cell lines, this clearly indicates that for lysosomal glycoproteins Man7 carrying one or two phosphate residues appears to be the major N-glycan involved in lysosomal targeting by the M6PR (Fig. 5B).


### Using glycomics to dissect glycosyltransferase specificity: FUT8 core-fucosylates a variety of oligomannose-type N-glycans

The substrate specificities of glycosyltransferases have traditionally been investigated in highly defined conditions that hardly can be considered to mimic the complex environment in which they have to act within the cell [35]. Core fucosylated oligomannose-type N-glycans have previously been reported in *MGAT1*-deficient (*Lec1*) Chinese hamster ovary (CHO) [36] and HEK293S cells [37], as well as in otherwise genetically unmodified porcine islet cells [38] and on human placental arylsulfatase A (though not confirmed by any MS2 fragmentation data) [39]. Yang et al. also identified that attachment of the N-glycan to a peptide/protein was a prerequisite for FUT8 to transfer a core-fucose onto an oligomannose-type N-glycan even in the absence of a GlcNAc on the  $\alpha$ 1-3 arm of the core mannose, while free oligomannose N-glycans remained unmodified by FUT8 in vitro [40]. In the analysed HNSCC cells, we found that core-fucose was attached to on Man4, Man5 and Man6 in up to 0.8% of all N-glycans (in SCC-9), while the levels of these N-glycans

were less than 0.1% in SCC-25 (Fig. 6A, Supplementary Table 2 and Supplementary Table 5). Next to SCC-9, both HPV expressing cell lines (VU-147 T and 2A3) showed slightly higher levels of these core fucosylated, oligomannose-type N-glycans, while the levels in the remaining two (CAL-27 and FaDu) were around 0.2% or lower (Fig. 6A). To the best of our knowledge, these data for the first time confirm by tandem MS data that *MGAT1*-independent core fucosylation on oligomannose-type N-glycans can occur in otherwise unmodified human cells in low levels (Fig. 6B).

### Discussion

Despite the increasing prevalence of HNSCC and its known association with HPV infection, the N-glycome of the cell lines most widely used in HNSCC research has not been studied. For the first time, we demonstrated that while these cell lines exhibit similar general profile, significant quantitative differences in their N-glycosylation features exist that make each of them unique research resources (Fig. 1B). As reported in comparable studies for colon cancer [41] or breast cancer cell lines [42], oligomannose-type N-glycans were the most prevalent N-glycans in HNSCC cells. The levels of complex-type N-glycans ranged between 24 and 36% (Fig. 1B), with most of them being sialylated (Table 1). Interestingly, the levels of paucimannose N-glycans, which were found to be a signature of many human cancer types [43], were low and below 5% except in VU-147 T cells (Fig. 1B). The levels of phosphorylated oligomannose-type



**Fig. 6** Core-fucosylation of oligomannose-type N-glycans. **A** Quantitation of core fucose attached oligomannose glycans. **B** Tandem MS data to identify oligomannose core-fucose structures

N-glycans, which are associated with lysosomal glycoproteins, were significantly higher just in SCC-9 and VU-147 T cells ( $\approx 6\%$ , Fig. 5A). This could indicate differences in the levels (and thus likely also activity) of lysosomal degradation pathways. The same two cell lines also exhibited the highest levels of core-fucosylated oligomannose-type N-glycans (Fig. 6A), despite the fact that these cell lines also showed comparably high levels of complex-type N-glycans (30.5% and 35.6%, respectively). Attachment of the N-glycan to a protein is a known prerequisite for FUT8 to transfer a fucose onto an oligomannose N-glycan [40], and the fact that these were highest in cell lines that also exhibited high levels of complex-type N-glycans could indicate that this modification is just restricted to specific glycoproteins.

Sialylation of tumour tissues has been correlated with cancer progression, metastatic spreading and poor prognosis across many different cancer types [44, 45, 46]. Most complex-type N-glycans in the analysed HNSCC cell lines carried at least one sialic acid, with  $\alpha 2$ -6 linked NeuAc residues being the dominant form of sialylation in all cell lines except SCC-9, where almost equal levels of  $\alpha 2$ -3 and  $\alpha 2$ -6 linked NeuAc residues were observed (Table 1, Fig. 3B). This could impact recognition of these HNSCC cell surface glycoproteins by Galectins, given that  $\alpha 2$ -3 NeuAc carrying LacNAc epitopes can be recognised by Galectin 1 and 3, while the  $\alpha 2$ -6 NeuAc capping blocks this recognition [47]. In oral squamous cell carcinoma

(OSCC), inhibition of Galectin-3 has been shown to overcome cetuximab-resistance in murine animal models [48]. Yin et al. showed that in cetuximab-resistant OSCC tumours, increased expression of Galectin-3, p-ERK1/2 and p-Akt was observed. The use of a Gal-3 inhibitor decreased the proliferation and invasion, while increasing the apoptosis of cetuximab-resistant HSC3 cells. These data clearly demonstrate an intrinsic role of these cell surface glycoconjugates and their interactions within the tumour microenvironment in immunotherapy.

The interplay between the different sialyltransferases known to add NeuAc residues onto N-glycans, such as ST6GAL1 or the ST3GAL4/5/6, clearly plays a major role in this context of the tumour microenvironment. The inhibition of  $\alpha 2$ -3 NeuAc expression has been demonstrated to suppress the migration and metastasis in melanoma cells [49]. ST6GAL1 has been reported earlier to be associated which enhanced growth, survival and metastasis in multiple cancers (including pancreatic, prostate, breast and ovarian cancer) [50]. Increased  $\alpha 2$ -6 NeuAc levels on the human epidermal growth factor receptor 2 (HER2) have been reported to facilitate gastric cancer progression and resistance via activation of the Akt and ERK pathways [51]. While there is some information about Galectin expression levels in head and neck and thyroid carcinomas [52, 53], their specific role, interaction partners and contributions to HNSCC pathogenesis and precision treatment remains still unknown.

This study provides for the first time a comprehensive mapping of the N-glycome from in six widely used HNSCC cell lines. Our data constitute the basis for further studies aiming at better understanding how changes in the HNSCC glycome may contribute to the pathogenesis of these highly heterogenous cancers. Moreover, identification of HNSCC-specific glycome modifications may be exploited to improve the predictive and prognostic definition of these patients and provide novel targets for improved treatments.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s00216-022-04376-x>.

**Acknowledgements** Chamindie Punyadeera is currently receiving funding from Cancer Australia (APP1145657), National Health and Medical Research Council (APP 2002576) and Medical Research Future Fund (MRFF) Rapid Applied Research Translation Program (Centre for Personalised Analysis of Cancers and RBWH Foundation). Daniel Kolarich (DK) is the recipient of an Australian Research Council Future Fellowship (project number FT160100344) funded by the Australian Government. This research is also supported by an Australian Government grant by project CE140100003 and by a Research Training Program (RTP) Scholarship to Mohammad Rasheduzzaman (MR).

**Funding** Open Access funding enabled and organized by CAUL and its Member Institutions

## Declarations

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Sklan A, Collingridge D. Treating head and neck cancer: for better or for worse? *Lancet Oncol*. 2017;18(5):570–1. [https://doi.org/10.1016/S1470-2045\(17\)30269-3](https://doi.org/10.1016/S1470-2045(17)30269-3).
2. Rasheduzzaman M, Kulasinghe A, Dolcetti R, Kenny L, Johnson NW, Kolarich D, Punyadeera C (2020) Protein glycosylation in head and neck cancers: from diagnosis to treatment. *Biochim Biophys Acta Rev Cancer*. 1874;2: 188422. <https://doi.org/10.1016/j.bbcan.2020.188422>.
3. Ovchinnikov DA, Wan Y, Coman WB, Pandit P, Cooper-White JJ, Herman JG, Punyadeera C. DNA methylation at the novel CpG sites in the promoter of MED15/PCQAP gene as a biomarker for head and neck cancers. *Biomark Insights*. 2014;9:53–60. <https://doi.org/10.4137/bmi.S16199>.
4. Schmidt H, Kulasinghe A, Kenny L, Punyadeera C. The development of a liquid biopsy for head and neck cancers. *Oral Oncol*. 2016;61:8–11. <https://doi.org/10.1016/j.oraloncology.2016.07.014>.
5. Jayaram SC, Muzaffar SJ, Ahmed I, Dhanda J, Paleri V, Mehanna H. Efficacy, outcomes, and complication rates of different surgical and nonsurgical treatment modalities for recurrent/residual oropharyngeal carcinoma: a systematic review and meta-analysis. *Head Neck*. 2016;38(12):1855–61. <https://doi.org/10.1002/hed.24531>.
6. Maxwell JH, Grandis JR, Ferris RL. HPV-associated head and neck cancer: unique features of epidemiology and clinical management. *Annu Rev Med*. 2016;67:91–101. <https://doi.org/10.1146/annurev-med-051914-021907>.
7. Lim Y, Wan Y, Vagenas D, Ovchinnikov DA, Perry CF, Davis MJ, Punyadeera C. Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers. *BMC Cancer*. 2016;16(1):749. <https://doi.org/10.1186/s12885-016-2785-0>.
8. Fujima N, Homma A, Harada T, Shimizu Y, Tha KK, Kano S, Mizumachi T, Li R, Kudo K, Shirato H. The utility of MRI histogram and texture analysis for the prediction of histological diagnosis in head and neck malignancies. *Cancer Imaging*. 2019;19(1):5. <https://doi.org/10.1186/s40644-019-0193-9>.
9. Yan K, Agrawal N, Gooi Z. Head and neck masses. *Med Clin North Am*. 2018;102(6):1013–25. <https://doi.org/10.1016/j.mcna.2018.06.012>.
10. Almeida A, Kolarich D (2016) The promise of protein glycosylation for personalised medicine. *Biochem Biophys Acta*. 1860;8:1583–95. <https://doi.org/10.1016/j.bbagen.2016.03.012>.
11. Vajaria BN, Patel KR, Begum R, Patel JB, Shah FD, Joshi GM, Patel PS. Salivary Glyco-sialylation changes monitors oral carcinogenesis. *Glycoconj J*. 2014;31(9):649–59. <https://doi.org/10.1007/s10719-014-9561-7>.
12. Guu S-Y, Lin T-H, Chang S-C, Wang R-J, Hung L-Y, Fang P-J, Tang W-C, Yu P, Chang C-F. Serum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients. *PLoS ONE*. 2017;12(6): e0178927. <https://doi.org/10.1371/journal.pone.0178927>.
13. Lin W-L, Lin Y-S, Shi G-Y, Chang C-F, Wu H-L. Lewisy promotes migration of oral cancer cells by glycosylation of epidermal growth factor receptor. *PLoS ONE*. 2015;10(3): e0120162. <https://doi.org/10.1371/journal.pone.0120162>.
14. Desiderio V, Papagerakis P, Tirino V, Zheng L, Matossian M, Prince ME, Paino F, Mele L, Papaccio F, Montella R, Papaccio G, Papagerakis S. Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells. *Oncotarget*. 2015;6(1):71–84. <https://doi.org/10.18632/oncotarget.2698>.
15. Chiang WF, Cheng TM, Chang CC, Pan SH, Changou CA, Chang TH, Lee KH, Wu SY, Chen YF, Chuang KH, Shieh DB, Chen YL, Tu CC, Tsui WL, Wu MH. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation. *Oncogene*. 2018;37(1):116–27. <https://doi.org/10.1038/ncr.2017.303>.
16. Hinneburg H, Korac P, Schirmeister F, Gasparov S, Seeberger PH, Zoldos V, Kolarich D. Unlocking cancer glycomes from histopathological formalin-fixed and paraffin-embedded (FFPE) tissue microdissections. *Mol Cell Proteomics*. 2017;16(4):524–36. <https://doi.org/10.1074/mcp.M116.062414>.
17. Jensen PH, Karlsson NG, Kolarich D, Packer NH. Structural analysis of N- and O-glycans released from glycoproteins. *Nat Protoc*. 2012;7(7):1299–310. <https://doi.org/10.1038/nprot.2012.063>.
18. Oliveira T, Zhang M, Joo EJ, Abdel-Aziz H, Chen CW, Yang L, Chou CH, Qin X, Chen J, Alagesan K, Almeida A, Jacob F, Packer NH, von Itzstein M, Heisterkamp N, Kolarich D. Glycoproteome

- remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia. *Theranostics*. 2021;11(19):9519–37. <https://doi.org/10.7150/thno.65398>.
19. Everest-Dass AV, Abrahams JL, Kolarich D, Packer NH, Campbell MP. Structural feature ions for distinguishing N- and O-linked glycan isomers by LC-ESI-IT MS/MS. *J Am Soc Mass Spectrom*. 2013;24(6):895–906. <https://doi.org/10.1007/s13361-013-0610-4>.
  20. Campbell MP, Abrahams JL, Rapp E, Struwe WB, Costello CE, Novotny M, Ranzinger R, York WS, Kolarich D, Rudd PM, Kettner C. The minimum information required for a glycomics experiment (MIRAGE) project: LC guidelines. *Glycobiology*. 2019;29(5):349–54. <https://doi.org/10.1093/glycob/cwz009>.
  21. Kolarich D, Rapp E, Struwe WB, Haslam SM, Zaia J, McBride R, Agravat S, Campbell MP, Kato M, Ranzinger R, Kettner C, York WS. The minimum information required for a glycomics experiment (MIRAGE) project: improving the standards for reporting mass-spectrometry-based glycoanalytic data. *Mol Cell Proteomics*. 2013;12(4):991–5. <https://doi.org/10.1074/mcp.O112.026492>.
  22. Struwe WB, Agravat S, Aoki-Kinoshita KF, Campbell MP, Costello CE, Dell A, Ten F, Haslam SM, Karlsson NG, Khoo KH, Kolarich D, Liu Y, McBride R, Novotny MV, Packer NH, Paulson JC, Rapp E, Ranzinger R, Rudd PM, Smith DF, Tiemeyer M, Wells L, York WS, Zaia J, Kettner C. The minimum information required for a glycomics experiment (MIRAGE) project: sample preparation guidelines for reliable reporting of glycomics datasets. *Glycobiology*. 2016;26(9):907–10. <https://doi.org/10.1093/glycob/cww082>.
  23. York WS, Agravat S, Aoki-Kinoshita KF, McBride R, Campbell MP, Costello CE, Dell A, Feizi T, Haslam SM, Karlsson N, Khoo KH, Kolarich D, Liu Y, Novotny M, Packer NH, Paulson JC, Rapp E, Ranzinger R, Rudd PM, Smith DF, Struwe WB, Tiemeyer M, Wells L, Zaia J, Kettner C. MIRAGE: the minimum information required for a glycomics experiment. *Glycobiology*. 2014;24(5):402–6. <https://doi.org/10.1093/glycob/cwu018>.
  24. Robin T, Mariethoz J, Lisacek F. Examining and fine-tuning the selection of glycan compositions with GlyConnect composer. *Mol Cell Proteomics*. 2020;19(10):1602–18. <https://doi.org/10.1074/mcp.RA120.002041>.
  25. Watanabe Y, Aoki-Kinoshita KF, Ishihama Y, Okuda S. Glyco-POST realizes FAIR principles for glycomics mass spectrometry data. *Nucleic Acids Res*. 2021;49(D1):D1523–8. <https://doi.org/10.1093/nar/gkaa1012>.
  26. Wan Y, Vagenas D, Salazar C, Kenny L, Perry C, Calvopiña D, Punyadeera C. Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients. *Oncotarget*. 2017;8(59):99990–100001. <https://doi.org/10.18632/oncotarget.21725>.
  27. Satapathy S, Batra J, Jeet V, Thompson EW, Punyadeera C. Micro-RNAs in HPV associated cancers: small players with big consequences. *Expert Rev Mol Diagn*. 2017;17(7):711–22. <https://doi.org/10.1080/14737159.2017.1339603>.
  28. Harris M, Wang XG, Jiang Z, Goldberg GL, Casadevall A, Dadachova E. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. *Head Neck Oncol*. 2011;3(1):9. <https://doi.org/10.1186/1758-3284-3-9>.
  29. Alam S, Anugraham M, Huang YL, Kohler RS, Hettich T, Winkelbach K, Grether Y, Lopez MN, Khasbiullina N, Bovin NV, Schlotterbeck G, Jacob F. Altered (neo-) lacto series glycolipid biosynthesis impairs alpha2-6 sialylation on N-glycoproteins in ovarian cancer cells. *Sci Rep*. 2017;7:45367. <https://doi.org/10.1038/srep45367>.
  30. Alagesan K, Everest-Dass A, Kolarich D. Isomeric separation and characterisation of glycoconjugates. *Adv Exp Med Biol*. 2018;1104:77–99. [https://doi.org/10.1007/978-981-13-2158-0\\_5](https://doi.org/10.1007/978-981-13-2158-0_5).
  31. Pabst M, Bondili JS, Stadlmann J, Mach L, Altmann F. Mass + retention time = structure: a strategy for the analysis of N-glycans by carbon LC-ESI-MS and its application to fibrin N-glycans. *Anal Chem*. 2007;79(13):5051–7. <https://doi.org/10.1021/ac070363i>.
  32. Moginger U, Grunewald S, Hennig R, Kuo CW, Schirmeister F, Voth H, Rapp E, Khoo KH, Seeberger PH, Simon JC, Kolarich D. Alterations of the human skin N- and O-glycome in basal cell carcinoma and squamous cell carcinoma. *Front Oncol*. 2018;8:70. <https://doi.org/10.3389/fonc.2018.00070>.
  33. Blanas A, Sahasrabudhe NM, Rodriguez E, van Kooyk Y, van Vliet SJ. Fucosylated antigens in cancer: an alliance toward tumor progression, metastasis, and resistance to chemotherapy. *Front Oncol*. 2018;8(39):39. <https://doi.org/10.3389/fonc.2018.00039>.
  34. Stanley P, Moremen KW, Lewis NE, Taniguchi N, Aeby M. N-Glycans. In: Varki A, Cummings RD, Esko JD, et al., editors. 4th edition, *Essentials of glycobiology*. Cold Spring Harbor (NY): 2022. p 103–116. <https://doi.org/10.1101/glycobiology.4e.9>.
  35. Taniguchi N, Honke K, Fukuda M, Narimatsu H, Yamaguchi Y, Angata T, editors. 2nd edition. *Handbook of glycosyltransferases and related genes*. Tokyo: Springer Japan; 2014. <https://doi.org/10.1007/978-4-431-54240-7>.
  36. Lin AI, Philipsberg GA, Haltiwanger RS. Core fucosylation of high-mannose-type oligosaccharides in GlcNAc transferase I-deficient (Lec1) CHO cells. *Glycobiology*. 1994;4(6):895–901. <https://doi.org/10.1093/glycob/4.6.895>.
  37. Yang Q, Wang LX. Mammalian alpha-1,6-fucosyltransferase (FUT8) is the sole enzyme responsible for the N-Acetylglucosaminyltransferase I-independent Core Fucosylation of High-mannose N-Glycans. *J Biol Chem*. 2016;291(21):11064–71. <https://doi.org/10.1074/jbc.M116.720789>.
  38. Nanno Y, Shajahan A, Sonon RN, Azadi P, Hering BJ, Burlak C. High-mannose type N-glycans with core fucosylation and complex-type N-glycans with terminal neuraminic acid residues are unique to porcine islets. *PLoS ONE*. 2020;15(11):e0241249. <https://doi.org/10.1371/journal.pone.0241249>.
  39. Hoja-Lukowicz D, Ciolczyk D, Bergquist J, Litynska A, Laidler P. High-mannose-type oligosaccharides from human placental aryl-sulfatase A are core fucosylated as confirmed by MALDI MS. *Glycobiology*. 2000;10(6):551–7. <https://doi.org/10.1093/glycob/10.6.551>.
  40. Yang Q, Zhang R, Cai H, Wang LX. Revisiting the substrate specificity of mammalian alpha1,6-fucosyltransferase reveals that it catalyzes core fucosylation of N-glycans lacking alpha1,3-arm GlcNAc. *J Biol Chem*. 2017;292(36):14796–803. <https://doi.org/10.1074/jbc.M117.804070>.
  41. Sethi MK, Thaysen-Andersen M, Smith JT, Baker MS, Packer NH, Hancock WS, Fanayan S. Comparative N-glycan profiling of colorectal cancer cell lines reveals unique bisecting GlcNAc and alpha-2,3-linked sialic acid determinants are associated with membrane proteins of the more metastatic/aggressive cell lines. *J Proteome Res*. 2014;13(1):277–88. <https://doi.org/10.1021/pr400861m>.
  42. Peng W, Mirzaei P, Zhu R, Zhou S, Mechref Y. Comparative membrane N-glycomics of different breast cancer cell lines to understand breast cancer brain metastasis. *J Proteome Res*. 2020;19(2):854–63. <https://doi.org/10.1021/acs.jproteome.9b00664>.
  43. Chatterjee S, Lee LY, Kawahara R, Abrahams JL, Adamczyk B, Anugraham M, Ashwood C, Sumer-Bayraktar Z, Briggs MT, Chik JHL, Everest-Dass A, Forster S, Hinneburg H, Leite KRM, Loke I, Moginger U, Moh ESX, Nakano M, Recuero S, Sethi MK, Srougi M, Stavenhagen K, Venkatakrishnan V, Wongtrakul-Kish

- K, Diestel S, Hoffmann P, Karlsson NG, Kolarich D, Molloy MP, Muders MH, Oehler MK, Packer NH, Palmisano G, Thaysen-Andersen M. Protein paucimannosylation is an enriched N-glycosylation signature of human cancers. *Proteomics*. 2019;19(21–22): e1900010. <https://doi.org/10.1002/pmic.201900010>.
44. Pearce OM, Laubli H. Sialic acids in cancer biology and immunity. *Glycobiology*. 2016;26(2):111–28. <https://doi.org/10.1093/glycob/cwv097>.
45. Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. *Br J Cancer*. 2021;124(1):76–90. <https://doi.org/10.1038/s41416-020-01126-7>.
46. Hedlund M, Ng E, Varki A, Varki NM. alpha 2–6-linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. *Cancer Res*. 2008;68(2):388–94. <https://doi.org/10.1158/0008-5472.CAN-07-1340>.
47. Gao C, Hanes MS, Byrd-Leotis LA, Wei M, Jia N, Kardish RJ, McKittrick TR, Steinhauer DA, Cummings RD. Unique binding specificities of proteins toward isomeric asparagine-linked glycans. *Cell Chem Biol*. 2019;26(4):535–547 e534. <https://doi.org/10.1016/j.chembiol.2019.01.002>.
48. Yin, P., Cui, S., Liao, X., & Yao, X. (2021). Galectin-3 blockade suppresses the growth of cetuximab-resistant human oral squamous cell carcinoma. *Molecular medicine reports*, 24(4), 685. <https://doi.org/10.3892/mmr.2021.12325>
49. Chang WW, Yu CY, Lin TW, Wang PH, Tsai YC. Soyasaponin I decreases the expression of alpha2,3-linked sialic acid on the cell surface and suppresses the metastatic potential of B16F10 melanoma cells. *Biochem Biophys Res Commun*. 2006;341(2):614–9. <https://doi.org/10.1016/j.bbrc.2005.12.216>.
50. Garnham R, Scott E, Livermore KE, Munkley J. ST6GAL1: a key player in cancer. *Oncol Lett*. 2019;18(2):983–9. <https://doi.org/10.3892/ol.2019.10458>.
51. Liu N, Zhu M, Linhai Y, Song Y, Gui X, Tan G, Li J, Liu Y, Deng Z, Chen X, Wang J, Jia L, He X, Wang X, Lin S. Increasing HER2 alpha2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways. *Oncol Rep*. 2018;40(5):2997–3005. <https://doi.org/10.3892/or.2018.6680>.
52. Kindt N, Journe F, Ghanem GE, Saussez S. Galectins and carcinogenesis: their role in head and neck carcinomas and thyroid carcinomas. *Int J Mol Sci*. 2017;18(12):2745. <https://doi.org/10.3390/ijms18122745>
53. Wan Y, Zhang X, Tang KD, Blick T, Kenny L, Thompson EW, Punyadeera C. Overexpression of miRNA-9 enhances galectin-3 levels in oral cavity cancers. *Mol Biol Rep*. 2021;48(5):3979–89. <https://doi.org/10.1007/s11033-021-06398-7>.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.